Kennett Square, PA, United States of America

William Frietze

USPTO Granted Patents = 16 (Patent Applications = 9)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 99(Granted Patents)

Location History:

Wilmington, DE (US) (2011 - 2015)
Kenneth Square, PA (US) (2021 - 2023)
Kennett Square, PA (US) (2002 - 2024)

Company Filing History:

Incyte Holdings Corporation

patents

3 out of 234

Bristol-myers Squibb Pharma Company

patents

4. 2 out of 3,681

Bristol-myers Squibb Compnay

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12024522 - Salts and processes of preparing a PI3K inhibitor (2024-07-02),

2. 11787784 - Solid forms of an HPK1 inhibitor (2023-10-17),

3. 11066394 - Solid forms of an HPK1 inhibitor (2021-07-20),

4. 10858372 - Amorphous solid form of a BET protein inhibitor (2020-12-08),

5. 10329305 - Amorphous solid form of a BET protein inhibitor (2019-06-25),

6. 10280157 - Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor (2019-05-07),

7. 9873688 - Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor (2018-01-23),

8. 9321755 - Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor (2016-04-26),

9. 9035065 - Ethanamine compounds and methods of using the same (2015-05-19),

10. 8013165 - Ethanamine compounds and methods of using the same 545 (2011-09-06),

11. 6589958 - Isoxazolo [4,5-d] pyrimidines as CRF antagonists (2003-07-08),

12. 6579876 - Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists (2003-06-17),

13. 6521636 - Imidazo-pyridines as corticotropin releasing factor antagonists (2003-02-18),

14. 6509338 - Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists (2003-01-21),

15. 6365589 - Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists (2002-04-02),

Title: The Innovative Contributions of William Frietze

Introduction

William Frietze is a notable inventor based in Kennett Square, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for various diseases. With a total of 16 patents to his name, Frietze's work has had a substantial impact on medical research and treatment options.

Latest Patents

Among his latest patents is a process for preparing a PI3K inhibitor, specifically (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one. This compound is useful as an inhibitor of phosphoinositide 3-kinase-delta (PI3Kδ). Another significant patent involves solid forms of an HPK1 inhibitor, which relates to salt forms of hematopoietic progenitor kinase 1 (HPK1) inhibitors. These compounds are essential in the treatment of HPK1 mediated diseases, including cancer.

Career Highlights

William Frietze has worked with prominent companies in the pharmaceutical industry, including Incyte Corporation and Incyte Holdings Corporation. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of drug discovery.

Collaborations

Throughout his career, Frietze has collaborated with talented individuals such as Jiacheng Zhou and Zhongjiang Jia. These partnerships have fostered innovation and have been instrumental in advancing his research projects.

Conclusion

William Frietze's contributions to the field of pharmaceuticals through his numerous patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of treatments for critical health issues.

This text is generated by artificial intelligence and may not be accurate.